Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.67 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.44 |
| ▸ | CCKAR | P32238 | 4/20 | 0.43 |
| ▸ | CCKBR | P32239 | 4/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27052536 | 1.00 | GLP1R (0.67) | GLP1RNOD1FOLH1CCKARCCKBR | |
| SCHEMBL14998187 | 1.00 | GLP1R (0.67) | GLP1RNOD1FOLH1CCKARCCKBR | |
| SCHEMBL16182588 | 0.98 | GLP1R (0.67) | GLP1RNOD1FOLH1CCKARCCKBR | |
| SCHEMBL71649 | 0.98 | GLP1R (0.67) | GLP1RNOD1FOLH1CCKARCCKBR | |
| SCHEMBL22402582 | 0.98 | GLP1R (0.67) | GLP1RNOD1FOLH1CCKARCCKBR | |
| SCHEMBL15975371 | 0.98 | GLP1R (0.67) | GLP1RNOD1FOLH1CCKARCCKBR | |
| SCHEMBL16182589 | 0.98 | GLP1R (0.67) | GLP1RNOD1FOLH1CCKARCCKBR | |
| SCHEMBL15358600 | 0.98 | GLP1R (0.67) | GLP1RNOD1FOLH1CCKARCCKBR | |
| SCHEMBL71264 | 0.93 | GLP1R (0.62) | GLP1RNOD1FOLH1 | |
| SCHEMBL13165198 | 0.93 | GLP1R (0.62) | GLP1RNOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556250-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2017-01-31 | — | — | US | disclosed |
| US-9486505-B2 | Glucagon analogues | NOVO NORDISK A/S (DK) | 2016-11-08 | — | — | US | disclosed |
| US-9365632-B2 | Exendin-4 derivatives as dual GLP1/glucagon agonists | SANOFI (FR) | 2016-06-14 | — | — | US | disclosed |
| US-8815802-B2 | GLP-1 analogues and derivatives | NOVO NORDISK A/S (DK) | 2014-08-26 | — | — | US | disclosed |
| US-20130143798-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2013-06-06 | — | — | US | disclosed |
| US-20130053311-A1 | GLP-1 ANALOGUES AND DERIVATIVES | NOVO NORDISK A/S (DK) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143798-A1 | NOVEL GLUCAGON ANALOGUES | GLP1R, GCG, IAPP | GLP1R 1/4885NOD1 1083/4885FOLH1 251/4885 |
| US-20130053311-A1 | GLP-1 ANALOGUES AND DERIVATIVES | GLP1R, IAPP, SLC5A1 | GLP1R 1/4885NOD1 221/4885FOLH1 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.